Address Risk Factors for BSI and SSI with Chlorhexidine Gluconate 2% w/v Impregnated Pad

Interventions designed to reduce Healthcare-Acquired Infections (HAIs) are vital to reduce risk of morbidity and mortality.

The European Centre for Disease Prevention and Control (ECDC) estimates that on any given day, about 80,000 patients, i.e. one in 18 patients, in European hospitals have at least one healthcare-associated infection.1 Of particular significance are bacteremia, a leading cause of HAIs.

The clinical evidence and education in this section, which includes information about an advanced preoperative cleansing regimen and general skin antisepsis, will help you implement a comprehensive program for your facility.

REFERENCE: 1. European Centre for Disease Prevention and Control, Press Release: Each day, one in 18 patients in European hospitals has a healthcare-associated infection: ECDC estimates, Stockholm, 4 July, 2013.

Targeted versus Universal Decolonization to Prevent ICU Infection
Susan S. Huang, M.D., M.P.H., et al.
N Engl J Med 2013; 368:2255-2265
View abstract

Effect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection
Michael W. Climo, M.D., et al.
N Engl J Med 2013; 368:533-542
View abstract

Preoperative shower revisited: can high topical antiseptic levels be achieved on the skin surface before surgical admission?
J Am Coll Surg. 2008 Aug;207(2):233-9
View abstract

Daily Bathing with 2% CHG Washcloths Leads to Almost Total Elimination of MRSA Bacteraemia
Wyncoll D, Shankar Hari M, Beale R
Department of Adult Critical Care, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
Download poster (PDF)
Prospective evaluation of 6 preoperative cutaneous antiseptic regimens for prevention of surgical site infection
Maki D, Paulson D
Poster Presented at SHEA Conference, March 2006.
Download poster (PDF)
Download handout (PDF)

Marketing Authorisation Holder:
Sage Products Coöperatief U.A., Herikerbergweg 238, Luna ArenA, 1101 CM, Amsterdam, Netherlands.

Name of Product:
Chlorhexidine Gluconate 2% w/v Impregnated Pad.

Dosage Form: Impregnated Pad

Cost: £299 per case of 40 packages.

Skin Antisepsis as part of an advanced preoperative cleansing regimen and general skin antisepsis. PL 43018/0001.

Warnings and Contra-Indications:
For external use only. Keep out of reach and sight of children. Do not use on premature or low birth weight infants or infants less than 2 months of age or receiving phototherapy. Do not use on patients with known allergies to chlorhexidine gluconate or any other ingredients in the product. Do not use immediately prior to any invasive techniques, such as venepuncture, lumbar puncture or surgery. Do not use on open skin wounds or broken skin. When using this product, keep out of eyes, ears, and mouth. May cause serious or permanent injury if chlorhexidine is permitted to enter and remain. If contact occurs, rinse with water right away. Do not use if irritation, sensitization, or allergic reaction occurs. Do not store above 25oC. Do not refrigerate or freeze. Store flat. Dispose of as solid waste. Do not flush pads in toilet. For posology, method of administration and side effects refer to SPC.

Supply Classifications: GSL

Date: September 2015